Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 1
1993 2
1994 1
1995 3
1996 3
1997 1
1998 4
1999 5
2000 5
2001 5
2002 8
2003 5
2004 8
2005 9
2006 7
2007 9
2008 15
2009 15
2010 26
2011 24
2012 24
2013 19
2014 32
2015 34
2016 35
2017 43
2018 43
2019 45
2020 39
2021 40
2022 41
2023 47
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Results by year

Filters applied: . Clear all
Page 1
CLL update 2022: A continuing evolution in care.
Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. Kay NE, et al. Blood Rev. 2022 Jul;54:100930. doi: 10.1016/j.blre.2022.100930. Epub 2022 Jan 26. Blood Rev. 2022. PMID: 35151528 Review.
High risk CLL is characterized as the presence of del17p13, TP53 mutations and complex karyotype. Multiple phase 3 clinical trials show that continuous therapy with novel agents such as Bruton tyrosine kinase inhibitors (BTKi) and B cell lymphoma 2 (BCL2) inhibitors …
High risk CLL is characterized as the presence of del17p13, TP53 mutations and complex karyotype. Multiple phase 3 clinical tr …
How I treat myelodysplastic syndromes of childhood.
Locatelli F, Strahm B. Locatelli F, et al. Blood. 2018 Mar 29;131(13):1406-1414. doi: 10.1182/blood-2017-09-765214. Epub 2018 Feb 8. Blood. 2018. PMID: 29438960 Free article. Review.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many children with MDSs and is routinely offered to all patients with MDS with excess of blasts, to those with MDS secondary to previously administered chemoradiotherapy, and to those with RC …
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many children with MDSs and is routinely offered to …
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Bernard E, et al. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3. Nat Med. 2020. PMID: 32747829 Free PMC article.
One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes w …
One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targ …
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH. Othman J, et al. Blood Adv. 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. Blood Adv. 2023. PMID: 37171402 Free PMC article. Clinical Trial.
MDS-related cytogenetics were present in 73% of the patients, with a complex karyotype in 49%. TP53 was the most common mutated gene, in 43%. ...
MDS-related cytogenetics were present in 73% of the patients, with a complex karyotype in 49%. TP53 was the most common mutate …
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. Weinberg OK, et al. Blood Adv. 2022 May 10;6(9):2847-2853. doi: 10.1182/bloodadvances.2021006239. Blood Adv. 2022. PMID: 35073573 Free PMC article.
A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show complex karyotype (CK), and these cases include a relatively high proportion of cases of therapy-related myeloid neoplasms and TP53 mutations. ...
A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show complex karyotype (CK), and these cases incl …
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Baliakas P, et al. Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2. Blood. 2019. PMID: 30602617 Free PMC article.
Recent evidence suggests that complex karyotype (CK) defined by the presence of 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemi …
Recent evidence suggests that complex karyotype (CK) defined by the presence of 3 chromosomal aberrations (structural and/or n …
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. Bersanelli M, et al. J Clin Oncol. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539200 Free PMC article.
Specific co-mutation patterns account for clinical heterogeneity within SF3B1- and SRSF2-related MDS. MDS with complex karyotype and/or TP53 gene abnormalities and MDS with acute leukemia-like mutations show poorest prognosis. ...
Specific co-mutation patterns account for clinical heterogeneity within SF3B1- and SRSF2-related MDS. MDS with complex karyotype …
Childhood myelodysplastic syndrome.
Chatterjee T, Choudhry VP. Chatterjee T, et al. Indian J Pediatr. 2013 Sep;80(9):764-71. doi: 10.1007/s12098-013-1130-8. Epub 2013 Aug 3. Indian J Pediatr. 2013. PMID: 23912822 Review.
The most effective and curative treatment is Hematopoietic stem cell transplantation and this is particularly effective in children with the monosomy 7 genetic defect as well as those displaying complex karyotype abnormalities provided it is instituted early in the …
The most effective and curative treatment is Hematopoietic stem cell transplantation and this is particularly effective in children with the …
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group. Grimwade D, et al. Blood. 2010 Jul 22;116(3):354-65. doi: 10.1182/blood-2009-11-254441. Epub 2010 Apr 12. Blood. 2010. PMID: 20385793 Free article. Clinical Trial.
Patients lacking the aforementioned favorable or adverse aberrations but with 4 or more unrelated abnormalities also exhibited a significantly poorer prognosis (designated "complex" karyotype group). These data allow more reliable prediction of outcome for patients …
Patients lacking the aforementioned favorable or adverse aberrations but with 4 or more unrelated abnormalities also exhibited a significant …
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Zavras PD, Sinanidis I, Tsakiroglou P, Karantanos T. Zavras PD, et al. Int J Mol Sci. 2023 Mar 6;24(5):5018. doi: 10.3390/ijms24055018. Int J Mol Sci. 2023. PMID: 36902450 Free PMC article. Review.
AML-MRC is distinguished from de novo AML by the presence of certain chromosomal abnormalities, such as deletion of 5q, 7/7q, 20q and complex karyotype and somatic mutations, which are also present in MDS and carry crucial prognostic implications. ...
AML-MRC is distinguished from de novo AML by the presence of certain chromosomal abnormalities, such as deletion of 5q, 7/7q, 20q and com …
515 results